Eli Lilly to Build 4 More Manufacturing Sites in Us
Eli Lilly announced it will increase its manufacturing capacity in the US by adding four new sites to produce key drug ingredients. The move is expected to create nearly 10,000 construction jobs during the buildout and 3,000 highly skilled workers once production commences. Eli Lilly plans to invest approximately $50 billion since 2020 to expand capacity.
- As the pharmaceutical industry grapples with supply chain disruptions and escalating tensions over trade policies, this bold move by Eli Lilly underscores the need for strategic investments in domestic manufacturing capacity.
- How will the increased focus on US production impact the sector's reliance on foreign suppliers, particularly China, which currently accounts for a significant proportion of API imports?